Diagnosis and management of aspergillosis in the Netherlands: A national survey

Mycoses

Volumn 59, Issue 2, 2016, Pages 101-107

  Lestrade, Pieter P A ^a,b,c   Meis, Jacques F ^a,b,c   Arends, Jan P ^d   van der Beek, Martha T ^e   de Brauwer, Els ^f   van Dijk, Karin ^g   de Greeff, Sabine C ^h   Haas, Pieter Jan ⁱ   Hodiamont, Caspar J ^j   Kuijper, Ed J ^e   Leenstra, Tjalling ^h   Muller, Anouk E ^k   Oude Lashof, Astrid M L ^l   Rijnders, Bart J ^m   Roelofsen, Eveline ⁿ   Rozemeijer, Wouter ^o   Tersmette, Mathijs ^p   Terveer, Elizabeth M ^e   Verduin, Cees M ^q   Wolfhagen, Maurice J H M ^r   Melchers, Willem J G ^a   Verweij, Paul E ^a,c   more..

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c National Mycology Reference Laboratory   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f Zuyderland Medical Centre   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

ⁱ UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^j ACADEMIC MEDICAL CENTER   (Netherlands)

^k MEDICAL CENTER HAAGLANDEN   (Netherlands)

^l MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^m ERASMUS MEDICAL CENTER   (Netherlands)

ⁿ Laboratory for Infectious Diseases   (Netherlands)

^o Northwest Clinics   (Netherlands)

^p ST ANTONIUS HOSPITAL   (Netherlands)

^q AMPHIA HOSPITAL   (Netherlands)

^r ISALA HOSPITAL   (Netherlands)

more..

Author keywords

Aspergillosis; Azole resistance; Treatment

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ITRACONAZOLE; POSACONAZOLE; PYRROLE; VORICONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS FUMIGATUS; FUNGUS IDENTIFICATION; HEALTH SURVEY; HUMAN; IN VITRO STUDY; INVASIVE ASPERGILLOSIS; NETHERLANDS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; ASPERGILLOSIS; DRUG EFFECTS; ISOLATION AND PURIFICATION; QUESTIONNAIRE;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG RESISTANCE, FUNGAL; HUMANS; NETHERLANDS; SURVEYS AND QUESTIONNAIRES; VORICONAZOLE;

EID: 84954026735     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/myc.12440     Document Type: Article

References (29)

1. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-60.
2. Maertens J, Marchetti O, Herbrecht R et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL3 2009 update. Bone Marrow Transplant 2011; 46: 709-18.
3. Snelders E, van der Lee HA, Kuijpers J et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5: e219.
4. van der Linden JW, Snelders E, Kampinga GA et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. Emerg Infect Dis 2011; 17: 1846-54.
5. van der Linden JW, Camps SM, Kampinga GA et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 2013; 57: 513-20.
6. Verweij PE, Meis JF, Rijnders B et al. Azole resistance in Aspergillus fumigatus. In: de Greeff SC, Mouton JW (eds). NethMap 2015. Consumption of Antimicrobial Agents and Antimicrobial Resistance Among Medically Important Bacteria in The Netherlands. National Institute for Public Health and the Environment: Bilthoven, the Netherlands, 2015: 113-15.
7. Russcher A, van Paassen J, Dofferhoff PA, Kuijper EJ. High azole resistance rate of Aspergillus fumigatus at intensive care unit in a Dutch tertiary hospital. Ned Tijdschr Med Microbiol 2014; 22(suppl): 121.
8. Fuhren J, Voskuil WS, Boel CHE et al. High prevalence of azole resistance in Aspergillus fumigatus isolates from high risk patients. J Antimicrob Chemother 2015; 70: 2894-8.
9. Verweij PE, Snelders E, Kema GH, Mellado E, Melchers WJ. Azole resistance in Aspergillus fumigatus: a side effect of environmental fungicide use? Lancet Infect Dis 2009; 9: 789-95.
10. Chowdhary A, Kathuria S, Xu J, Meis JF. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog 2013; 9: e1003633.
11. van der Linden JWM, Arendrup MC, Warris A et al. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis 2015; 21: 1041-4.
12. Chowdhary A, Sharma C, van den Boom M et al. Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. J Antimicrob Chemother 2014; 69: 2979-83.
13. Kidd SE, Goeman E, Meis JF, Slavin MA, Verweij PE. Multi-triazole-resistant Aspergillus fumigatus infections in Australia. Mycoses 2015; 58: 350-5.
14. 34/L98H mutations in Turkey. J Infect Chemother 2015; 21: 581-6.
15. Ahmad S, Khan Z, Hagen F, Meis JF. Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in Kuwait. Environ Res 2014; 133: 20-26.
16. 46/Y121F/T289A mutation in France. Antimicrob Agents Chemother 2015; 59: 4331-5.
17. 34/L98H mutations in the cyp51A gene in Iran. Mycoses 2013; 56: 659-63.
18. Chowdhary A, Sharma C, Kathuria S, Hagen F, Meis JF. Prevalence and mechanism of triazole resistance in Aspergillus fumigatus in a referral chest hospital in Delhi, India and an update of the situation in Asia. Front Microbiol 2015; 6: 428.
19. 34/L98H mutations in Taiwan. Mycoses 2015; 58: 544-9.
20. Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis 2015; pii: civ885.
21. Wiederhold NP, Garcia Gil V, Lindner J et al. Evaluation of Cyp51A mechanisms of azole resistance in Aspergillus fumigatus isolates from the United States. Mycoses 2015; 58(suppl 4): 55.
22. Ahmad S, Joseph L, Hagen F, Meis JF, Khan Z. Concomitant occurrence of itraconazole-resistant and -susceptible strains of Aspergillus fumigatus in routine cultures. J Antimicrob Chemother 2015; 70: 412-15.
23. Meis JF, de Lorijn R, Curfs-Breuker I et al. Multicenter surveillance of azole-resistant Aspergillus fumigatus isolates in non-academic teaching hospitals in the Netherlands. Mycoses 2015; 58(suppl 4): 60.
24. Howard SJ, Cerar D, Anderson MJ et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 2009; 15: 1068-76.
25. Oude Lashof AML, Janssen JJWM, Meis JF et al. Optimaliseren van het antibioticabeleid in Nederland. XIII. SWAB-richtlijn voor de behandeling van invasieve schimmelinfecties. Ned Tijdschr Geneeskd 2009; 153: A901.
26. Verweij PE, Ananda-Rajah M, Andes D et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat 2015; 21-22: 30-40.
27. van der Linden JW, Snelders E, Arends JP, Daenen SM, Melchers WJ, Verweij PE. Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens. J Clin Microbiol 2010; 48: 1478-80.
28. Denning DW, Park S, Lass-Florl C et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 2011; 52: 1123-9.
29. Chong GL, van de Sande WW, Dingemans GJ et al. Validation of a new Aspergillus real-time PCR assay for direct detection of Aspergillus and azole resistance of Aspergillus fumigatus on bronchoalveolar lavage fluid. J Clin Microbiol 2015; 53: 868-74.